SARS-CoV-2 Doggybone DNA Vaccine Produces Cross-Variant Neutralizing Antibodies and Is Protective in a COVID-19 Animal Model

To combat the COVID-19 pandemic, an assortment of vaccines has been developed. Nucleic acid vaccines have the advantage of rapid production, as they only require a viral antigen sequence and can readily be modified to detected viral mutations. Doggybone™ DNA vaccines targeting the spike protein of S...

Full description

Bibliographic Details
Main Authors: Eric M. Mucker, Rebecca L. Brocato, Lucia M. Principe, Robert K. Kim, Xiankun Zeng, Jeffrey M. Smith, Steven A. Kwilas, Sungwon Kim, Helen Horton, Lisa Caproni, Jay W. Hooper
Format: Article
Language:English
Published: MDPI AG 2022-07-01
Series:Vaccines
Subjects:
Online Access:https://www.mdpi.com/2076-393X/10/7/1104